參考資訊

參考資訊

1. Jardiance Hong Kong prescribing information.
2. U.S. Food and Drug Administration (FDA). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=204629. (Last accessed: Jul 2024).
3. European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance. (Last accessed: Jul 2024).
4. Schernthaner G, et al. Therapeutics and Clinical Risk Management. 2017;13:69-79.
5. Frampton J.E. Drugs(2018)78:1037-1048.
6. Zinman B, et al. N Engl J Med. 2015; 373(22), 2117-2128.
7. Packer M, Anker SD, Butler J, et al; EMPEROR-Reduced Trial Investigators Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.​
8. Anker SD, Butler J, Filippatos G, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461.
9. Herrington WG, Staplin N, Wanner C, et al. EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117-127